December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Rashid Sayyid: RW study of LuPSMA in VISION-eligible mCRPC patients
Jun 11, 2024, 22:40

Rashid Sayyid: RW study of LuPSMA in VISION-eligible mCRPC patients

Rashid Sayyid, Urologic Oncology Clinical Fellow at University of Toronto, shared a post on X:

“RW study of LuPSMA in VISION-eligible mCRPC patients from expanded access program (UCLA, UCSF, Tulane, Johns Hopkins; n=117) compared to VISION phase 3 results.

  • RW patients more likely to have received >1 ARPI (70% versus 46%), have worse PS, and have LN disease
  • Similar OS (15.1) and PSA50 (42%)
  • Increased incidence of Gr3+ lymphopenia in RW (34% versus 8%)

Results support use of LuPSMA in RW setting.”

Rashid Sayyid: RW study of LuPSMA in VISION-eligible mCRPC patients

Source: Rashid Sayyid/X